FGFR3–TACC3 is reported to be a relapsing drug resistance mechanism that can bypass EGFR blockade by all generations of EGFR TKI in NSCLC (Ou et al. 2017). This evidence concerns the gene EGFR and non-small cell lung carcinoma.